Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was -5.69% in last session and finished the day at $29.48. Traded volume was 263,884 million shares in the last session and the average volume of the stock remained 254.15 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 0.40%.

Cell Therapeutics Inc (NASDAQ:CTIC)’s shares dropped 3.02% to $3.85. The company on Feb. 27 reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final guidance recommending prescription of PIXUVRI® (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma. Cell Therapeutics Inc (NASDAQ:CTIC) dropped percent to -5.71% yesterday on volume of 5.63 million shares. The intra-day range of the stock was $3.51 to $3.74. Cell Therapeutics Inc (NASDAQ:CTIC) has a market capitalization of $530.66 million.

Shares of NewLink Genetics Corp (NASDAQ:NLNK), a clinical-stage biopharmaceutical company developing immunotherapeutic options to help treat cancer, fell as much as 13% after receiving a downgrade. NewLink Genetics Corp (NASDAQ:NLNK)’s stock on Mar 3, 2014 reported a decrease of -11.58% to the closing price of $39.08. Its fifty two weeks range is $11.19 -$53.48. The total market capitalization recorded $1.00 billion. The overall volume in the last trading session was 1,121,761 million shares. In its share capital, NewLink Genetics Corp (NASDAQ:NLNK) has 25.70 million outstanding shares.

On Feb 5 Mirati Therapeutics, Inc. (NASDAQ:MRTX) presented the 2014 Leerink Global Healthcare Conference on Thursday, February 13 at 1:00 PM Eastern Time in New York. On Monday, shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) dropped -5.92% to close the day at $22.89. Its monthly performance is recorded as 9.42%. Mirati Therapeutics, Inc. (NASDAQ:MRTX) quarterly revenue growth is 34.65%.